Atypical Reactivation of Varicella Zoster Virus Associated with Pancreatitis in a Heart Transplant Patient

Christine Shieh
Ashley Barnes
Drew M. Johnson
Ilya M. Danelich
Preethi Pirlamarla
Rene Alvarez
Howard Massey
Mahek Shah

Corresponding Author:
Christine Shieh, e-mail: christine.shieh@jefferson.edu

Conflict of interest:
None declared

Patient: Male, 46-year-old
Final Diagnosis: Varicella zoster virus infection
Symptoms: Abdominal and/or epigastric pain
Medication: —
Clinical Procedure: Biopsy
Specialty: Cardiology • Gastroenterology and Hepatology • Infectious Diseases • Transplantology

Objective: Rare disease
Background: Acute pancreatitis is rare following solid organ transplantation but is associated with high mortality. It has been most commonly reported following renal transplant but can occur with other solid organ transplantations.

Case Report: A 46-year-old male who had an orthotopic heart transplant 6 months ago presented with a 3-week history of abdominal pain. The patient described it as intermittent, sharp, and stabbing, originating in the periumbilical area and radiating to the back. His lipase was elevated at 232 U/L. Given that the patient’s symptoms and lipase were elevated to greater than three times the upper limit of normal, he patient was diagnosed with acute pancreatitis. The patient also mentioned a diffuse itchy rash that started a few days prior to admission. Dermatology was consulted, and given the man’s clinical presentation, there was concern for atypical reactivation of varicella zoster virus (VZV). VZV polymerase chain reaction of the vesicles returned positive. The patient was started on acyclovir and his symptoms improved.

Conclusions: This is the first reported case of VZV-associated pancreatitis in a heart transplant patient. Our patient presented with acute pancreatitis and was treated supportively. However, he did not receive antiviral treatment until his rash was discovered. Timely treatment of VZV resulted in resolution of both the rash and pancreatitis. Timely diagnosis of pancreatitis and VZV is important to prevent development of multiorgan failure and death.

MeSH Keywords: Abdominal Pain • Heart Transplantation • Herpesvirus 3, Human • Immunosuppression • Pancreatitis

Full-text PDF: https://www.amjcaserep.com/abstract/index/idArt/923969
Background

Acute pancreatitis is rare following solid organ transplantation but is associated with high mortality [1]. It has most commonly been reported following renal transplant, with an incidence ranging from 2% to 7% and a 50% to 100% mortality rate [2]. Acute pancreatitis is known to occur after heart transplantation, especially in the early postoperative period [3]. Given the high morbidity and mortality associated with such cases, early recognition and identification of a reversible etiology remains key. Common etiologies of pancreatitis in immunocompetent patients include gallstones, alcohol use, and medications. Among solid organ transplant recipients who are immunosuppressed, specific etiologies such as steroid use, azathioprine, and cytomegalovirus (CMV) reactivation have also been reported [1]. While only a few cases of pancreatitis in renal transplant patients have been attributed to VZV, some patients became critically ill and died from disseminated disease [4]. Here, we present the first reported case of acute pancreatitis associated with atypical reactivation of VZV presenting as a varicella-like rash in a heart transplant recipient.

Case Report

A 46-year-old male with a history of non-ischemic dilated cardiomyopathy who had an orthotopic heart transplant 6 months prior presented with a 3-week history of abdominal pain. The patient thought the pain was from lifting, but it had gotten progressively worse over the last few days. Other medical history included chronic obstructive pulmonary disorder, pulmonary sarcoidosis, hypertension, and diabetes. At the time of presentation, the patient was on triple immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone.

The patient described his abdominal pain as intermittent, sharp, and stabbing, originating in the periumbilical area and radiating to the back. Associated symptoms included decreased oral intake, nausea, and vomiting. Work-up in the emergency department 3 days prior for mild abdominal pain included a computed tomography scan of the abdomen, which revealed no evidence of pancreatitis, cholecystitis, colitis, hydronephrosis, or gallstones. During the patient’s current hospitalization, his blood alcohol and triglyceride levels were within normal limits. His blood lipase was elevated at 232 U/L, up trending from 130 U/L 3 days previously. Given the patient’s symptoms and lipase being elevated to greater than three times the upper limit of normal, he was diagnosed with acute pancreatitis.

The patient was admitted to the inpatient service and was in mild-moderate distress from the abdominal pain. He was started on supportive care for acute pancreatitis with intravenous fluids and opioids for pain control. An abdominal ultrasound showed no evidence of gall stones, or gallbladder wall thickening. The etiology of the pancreatitis remained unclear. The patient’s steroid dose was halved and atorvastatin was discontinued in case it was contributory.

The patient mentioned an itchy rash over his body that started a few days prior to admission and had progressed since. The rash was noted to be vesicular, erythematous, diffuse on his neck, back, and groin, and present on both sides of the midline (Figure 1A). He denied sick contacts and reported a remote history of chicken pox. A review of previous records demonstrated presence of pre-transplant immunoglobulin G (IgG) varicella zoster virus (VZV) antibodies. Dermatology was consulted and described the lesions as vesicles on an erythematous base with mycophenolate mofetil, tacrolimus, and prednisone.

The lesions were in multiple stages of development, there was concern for atypical reactivation of VZV that appeared

Figure 1. Non-dermatomal distribution of rash over back in various stages of healing (A). Close-up of vesicular lesions on erythematous base (B).
Conclusions

Patients

Our patient presented with a subtle rash that appeared more like VCV than HZV despite the prior history of chickenpox. Incidence of pancreatitis among heart transplant recipients can range from 2% to 18%, significantly higher than for other cardiac procedures [5]. However, the diagnosis may be delayed due to subtler clinical presentations and the potentially large differential diagnoses for abdominal pain post solid organ transplant. While gallstones and alcohol intake are the most common causes, other etiologies in immunocompromised patients, such as drugs or opportunistic infections, must be entertained.

Discussion

To our knowledge, this is the first reported case of VZV-associated pancreatitis in a heart transplant patient. Our patient presented with a subtle rash that appeared more like VCV than HZV. The patient was started on acyclovir 10 mg/kg q8h for 7 to 10 days and placed on airborne precaution within hours of suspicion for disseminated VZV. His symptoms improved with continued supportive care for pancreatitis. After the lesions crusted over, the patient was transitioned to oral valacyclovir to complete a 10-day course. He was discharged and followed up in transplant clinic, where the symptoms had completely resolved and lipase levels were back within normal limits (31 U/L). He continues to have an uneventful post-transplant course.

Table 1. A review of disseminated VZV cases predominantly reported in renal transplant patients in the past.

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients</th>
<th>Outcomes</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single center retrospective study Mustapic et al. [11]</td>
<td>40 renal transplant patients, 5 of which had disseminated VZV</td>
<td>No deaths: Complications: 7 with cutaneous scarring, 2 with post-herpetic neuralgia, and 5 relapsed. Immunosuppression was decreased for the relapsed patients</td>
<td>Frequency and intensity of VZV infections is associated with degree of immunosuppression, particularly MMF. High-dose acyclovir and reduction of immunosuppression is important for treatment</td>
</tr>
<tr>
<td>Metanalysis 1985–2011 Rommelaere et al. [10]</td>
<td>56 adult renal transplant patients with disseminated VZV</td>
<td>Mortality rate: 47% before 1995 and 17% after 1995. Complications: 2/3 with disseminated intravascular coagulation</td>
<td>Disseminated VZV is life threatening but the mortality rate has decreased since 1995. Seropositive VZV patients with disseminated infection can still have fatal outcome</td>
</tr>
<tr>
<td>Retrospective study 2003–2013 Chitasombat et al. [12]</td>
<td>22 renal transplant patients with disseminated VZV</td>
<td>No deaths: All were treated with systemic acyclovir for 3–31 days. Immunosuppression reduced for 59% of patients</td>
<td>Incidence of disseminated VZV post kidney transplant is low. Treatment with IV acyclovir and reduction of immunosuppression provides a favorable outcome in resource limited environments</td>
</tr>
<tr>
<td>Single center case report series Fehr et al. [13]</td>
<td>4 renal transplant patients with disseminated VZV</td>
<td>No deaths: Complications: hepatitis, pneumonitis, disseminated intravascular coagulation</td>
<td>Further literature search reveals a high mortality rate of 34% but this has decreased in the recent years. High-dose acyclovir is the drug of choice</td>
</tr>
</tbody>
</table>

VZV – varicella zoster virus.

more like varicella than herpes zoster in the setting of immunosuppression. The vesicles were swabbed for VZV polymerase chain reaction (PCR testing), which returned positive. A Tzanck smear showed giant multinucleated keratinocytes, confirming the PCR findings. VZV PCR and both VZV immunoglobulin M (IgM) and IgG antibodies tested positive in blood. CMV and herpes simplex virus PCR were negative.

The patient was started on acyclovir 10 mg/kg q8h for 7 to 10 days and placed on airborne precaution within hours of suspicion for disseminated VZV. His symptoms improved with continued supportive care for pancreatitis. After the lesions crusted over, the patient was transitioned to oral valacyclovir to complete a 10-day course. He was discharged and followed up in transplant clinic, where the symptoms had completely resolved and lipase levels were back within normal limits (31 U/L). He continues to have an uneventful post-transplant course.

Our patient met the Atlanta criteria for pancreatitis based on his lipase level and clinical presentation although his imaging was negative. Nearly all common etiologies of pancreatitis were ruled out in this patient; however, his symptoms did not begin to resolve until he initiated antiviral treatment for VZV. Although VZV may not be an irrefutable cause of his pancreatitis, the association between VZV and visceral organ involvement in immunosuppressed patients has been documented in the literature and should not be overlooked. In nearly all cases, the presentation of visceral involvement preceded the VZV rash, and a delayed diagnosis of VZV resulted in organ failure and death [6]. A study by Locksley et al. on VZV infection in bone marrow transplant recipients found that 21% had visceral symptoms before skin manifestations [7]. Cases

Table 1. A review of disseminated VZV cases predominantly reported in renal transplant patients in the past.
of VZV-induced pancreatitis have been described in immunocompetent patients as well [8].

This case and other similar cases presented previously in renal transplant patients (Table 1) reinforce the importance of preventing VZV infection in immunocompromised patients [10–13]. Our patient had prior immunity to varicella, as evidenced by a reactive VZV IgG antibody, but interestingly, presented with what appears to be VZV despite no recent sick contacts with positive IgM and IgG serology. IgM serology can provide evidence for a recent active VZV infection, but does not discriminate between a primary infection and reinfecion or reactivation of latent infection due to transient increase in specific IgM antibodies on such re-exposure to VZV. Thus, we hypothesize that our patient likely represents a case of VZV reactivation from previous latency. In general, all potential transplant patients should undergo serologic testing and seronegative patients should be vaccinated prior to the surgery [9]. Those who are not vaccinated and are exposed post-transplant should receive VZV immunoglobulin or acyclovir [9]. Therapy with acyclovir or alternative equivalent antiviral therapies should be initiated within 24 to 72 hours of symptom onset to maximize efficacy.

Conclusions

In summary, timely diagnosis of pancreatitis in the setting of disseminated VZV is important in immunocompromised patients to prevent development of multiorgan failure and death. Identification of the appropriate etiology for pancreatitis in post-transplant patients requires maintaining a high suspicion for alternative diagnosis beyond conventional known risk factors.

Acknowledgements

The authors thank Dr. Matthew Scott Keller and Dr. Christina Ring from Dermatology for their assistance in confirming VZV diagnosis from vesicle smears and Dr. Nana Aburjurnia from Transplant Infectious Disease for assistance with treatment.

References: